Peptides News and Research

RSS

Scientists detect molecular obesity link to insulin resistance, type II diabetes

A molecular switch found in the fat tissue of obese mice is a critical factor in the development of insulin resistance, report scientists at the Salk Institute for Biological Studies.

2 Apr 2009

Is telmisartan effective in treating non-alcoholic steatohepatitis?

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

2 Apr 2009

New understanding on how probiotics can prevent disease

Using probiotics successfully against a number of animal diseases has helped scientists from University College Cork, Ireland to understand some of the ways in which they work, which could lead to them using probiotics to prevent and even to treat human diseases.

1 Apr 2009

A magic bullet for superbugs

Attaching an antimicrobial drug, which is activated by light, to a peptide that binds to bacteria and stops them making toxins, produced a "magic bullet" that was highly effective at killing the superbug, methicillin-resistant Staphylococcus aureus (MRSA).

1 Apr 2009

Novel assays provide new insight into why patients are in heart failure

A failing heart makes a lot of a hormone needed to eliminate the excess salt and water bloating the body but not enough of the enzyme needed to activate it, researchers say.

1 Apr 2009

Quantum Immunologics announces the filing of two important provisional patent applications

Quantum Immunologics, Inc. (QI), a Florida-based company specializing in cancer immunotherapy, has recently filed two provisional patent applications relating to their work in cancer immunotherapy.

31 Mar 2009

Moonlighting immune molecules found in the brain

Molecules assumed to be in the exclusive employ of the immune system have been caught moonlighting in the brain - with a job description apparently quite distinct from their role in immunity.

30 Mar 2009

Melatonin may be served as a potential anti-fibrotic drug

In China, the incidence of liver cirrhosis is still high. Liver cirrhosis results from fibrosis. If treated properly at fibrosis stage, cirrhosis can be prevented.

30 Mar 2009

Corthera's Relaxin in acute heart failure shows promising results

Corthera Inc. has announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, placebo-controlled international study, demonstrated promising efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure (AHF).

30 Mar 2009

Nile Therapeutics update on phase II CD-NP trial for acute heart failure

Nile Therapeutics, Inc. has announced that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile submitted to the U.S. Food and Drug Administration (FDA) to support the initiation of the Company's Phase IIb clinical trial with CD-NP for the treatment of acute heart failure, the FDA has placed CD-NP on clinical hold.

30 Mar 2009

New tool in the radiography approach will assist in earlier detection of asbestos-related diseases

Michael Harbut, M.D., MPH, co-director of the National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) at the Barbara Ann Karmanos Cancer Institute in Detroit, MI, and chief of the Center for Occupational and Environmental Medicine Wayne State University, announced the use of a new technology to aid in the diagnosis of asbestos-related lung disease.

30 Mar 2009

Improved predictive value of biomarkers in HF makes earlier diagnosis and better management possible

With an ever ageing population and more people surviving a heart attack, heart failure is now the world's most prevalent chronic cardiovascular disease.

29 Mar 2009

Improved predictive value of biomarkers in heart failure now makes earlier diagnosis and better management possible

With an ever ageing population and more people surviving a heart attack, heart failure is now the world's most prevalent chronic cardiovascular disease.

29 Mar 2009

RegeneRx reports phase II venous stasis trial results

Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.

29 Mar 2009

Twin nanoparticle shown effective at targeting, killing breast cancer cells

A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.

26 Mar 2009